Kura Oncology director granted 35,000 stock options

Kura Oncology director Carol Schafer received a grant of stock options, acquiring options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share.

Rhea-AI Filing Summary

Kura Oncology director Carol Schafer received a grant of stock options, acquiring options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. These options vest in full on the one-year anniversary of the grant date and expire on June 3, 2036. Following this compensation-related award, Schafer holds 35,000 options directly, with no indication of open-market buying or selling in this filing.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider SCHAFER CAROL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	35,000	$0.00	$0.00

Holdings After Transaction: Option to purchase common stock — 35,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests in full on the one year anniversary of the date of grant.

Key Figures

Options granted: 35,000 options Exercise price: $8.77 per share Expiration date: June 3, 2036 +2 more

5 metrics

Options granted 35,000 options Grant of options to purchase common stock

Exercise price $8.77 per share Exercise price for newly granted options

Expiration date June 3, 2036 Option term end date

Total options after grant 35,000 options Derivative securities beneficially owned following transaction

Vesting schedule 100% after one year Option vests in full on one-year anniversary of grant

Key Terms

Option to purchase common stock, exercise price, expiration date, Grant, award, or other acquisition, +1 more

5 terms

Option to purchase common stock financial

"security_title: Option to purchase common stock"

exercise price financial

"conversion_or_exercise_price: 8.7700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vests in full financial

"This option vests in full on the one year anniversary of the date of grant."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kura Oncology (KURA) report for Carol Schafer?

Kura Oncology reported a stock option grant to director Carol Schafer. She received options to purchase 35,000 shares of common stock as a compensation-related award, rather than through open-market buying or selling of existing shares.

How many Kura Oncology (KURA) shares are covered by Carol Schafer’s new options?

The new grant covers 35,000 shares of Kura Oncology common stock. These shares are not issued immediately; they become purchasable only if Schafer exercises the options after they vest and before they expire.

What is the exercise price of Carol Schafer’s Kura Oncology (KURA) stock options?

The options have an exercise price of $8.77 per share. This means Schafer can buy Kura Oncology common stock at $8.77 for each of the 35,000 optioned shares once they are vested and while the options remain outstanding.

When do Carol Schafer’s Kura Oncology (KURA) options vest and expire?

The options vest in full one year after the grant date and expire June 3, 2036. Schafer must wait for full vesting after one year, then has until the June 3, 2036 expiration date to exercise the options.

Is Carol Schafer’s Kura Oncology (KURA) Form 4 transaction a market purchase or sale?

No, the Form 4 reflects a compensation grant, not a market trade. The transaction is coded as a grant or award of derivative securities, so it does not represent buying or selling shares on the open market.

How many Kura Oncology (KURA) options does Carol Schafer hold after this grant?

After the reported transaction, Carol Schafer holds 35,000 options. The Form 4 lists total derivative securities beneficially owned following the transaction as 35,000 options to purchase Kura Oncology common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHAFER CAROL

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$8.77	06/04/2026		A		35,000		(1)	06/03/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. This option vests in full on the one year anniversary of the date of grant.

	/s/ Teresa Bair, Attorney-in-fact for Carol Schafer	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)